Rapid Platelet Inhibition

Aggrastat achieves > 90% platelet inhibition within 10 minutes. Contact Us Aggrastat Pharmacy Product Image

Medicure Pharma reintroduced the AGGRASTAT 5MG/100ML BAGS (NDC: 25208-0002-01) product earlier this year. It is the same concentration, ready-to-use format, storage and stability properties, and price as the AGGRASTAT 5MG/100ML VIALS (NDC: 25208-0002-03). The 5MG/100ML vial format will no longer be manufactured. The 5MG/100ML bag will replace the 5MG/100ML vial. If you require any assistance working with your wholesaler, please contact our ordering department at 1-800-509-0544 or

Most used GPI in the U.S. and worldwide


The #1 used GPI in the U.S.


20+ years on the market since approval of first indication in 1998.


Over 20 years of clinical research.


Used in over 400,000 patients since 2013.

Aggrastat Vial Bolus Real

How to order Aggrastat®

Aggrastat® is available through normal distribution at your wholesaler. For immediate supply, Aggrastat® is available as a drop shipment via Express Overnight Delivery. It is important to provide your wholesaler with updated demand forecasts for Aggrastat®.
Important Safety Information


Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

or call 1-800-FDA-1088.